Characterization of a Novel Phage HZJ33 and Its Application in the Treatment of Carbapenem‐Resistant Klebsiella pneumoniae Infection

CFU/mL). These findings identify HZJ33 as a lytic phage with a broad host range, high stability, favorable safety, and strong antibacterial activity in vitro and in vivo, supporting its potential for CRKP therapy.